Evaluation of implant stability and marginal bone loss in immediate implant using “nano bone” versus “autogenous bone” for the treatment of patients with unrestorable single tooth: a randomized controlled trial
Aim A randomized controlled trial was conducted to evaluate the advantages of using nano-hydroxyapatite (nHA) bone graft compared to the "gold standard" autogenous bone graft in the jumping gap with immediate implants.
Materials and methods Immediate implant placement was performed for the treatment of patients with an unrestorable single tooth. All eligible patients, in total 18, were randomly selected and divided in two groups, controls (AG) and study group (NB), in equal proportions (9 for eah group). Six month later implants were surgically exposed and the measurements of the secondary outcomes were taken.
Results Implant stability outcomes showed no significant differences in the groups. Marginal bone level of both groups at baseline and after six months showed a significant difference, as bone loss occurred more in NB group than AG group.
Conclusion Within the limits of the present study the placement of NB graft in the jumping gap contributed in decreasing and reduced the morbidity of the donor site compared to autogenous bone (AB) group. Trial had been registered in both The Pan African Clinical Trials Registry (PACTR) PACTR201512001348246 and clinical trial.gov NCT02613663.
PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.